296 related articles for article (PubMed ID: 19206083)
21. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Ferrara F; D'Arco AM; De Simone M; Mele G; Califano C; Pocali B; Danise P; Palmieri S
Haematologica; 2005 Jun; 90(6):776-84. PubMed ID: 15951290
[TBL] [Abstract][Full Text] [Related]
23. High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
Ferrara F; Annunziata M; Schiavone EM; Copia C; De Simone M; Pollio F; Palmieri S; Viola A; Russo C; Mele G
Hematol J; 2001; 2(4):214-9. PubMed ID: 11920252
[TBL] [Abstract][Full Text] [Related]
24. High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
Meloni G; Capria S; Trasarti S; Ferrazza G; Micozzi A; Petrucci MT; Simone F; Trisolini SM; Mandelli F
Bone Marrow Transplant; 2000 Nov; 26(10):1045-9. PubMed ID: 11108301
[TBL] [Abstract][Full Text] [Related]
25. Idarubicin in induction treatment of acute myeloid leukemia in the elderly.
Leoni F; Ciolli S; Nozzoli C; Marrani C; Caporale R; Ferrini PR
Haematologica; 1997; 82(5 Suppl):13-8. PubMed ID: 9402748
[TBL] [Abstract][Full Text] [Related]
26. High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?
Hong M; Miao KR; Zhang R; Lu H; Liu P; Xu W; Chen LJ; Zhang SJ; Wu HX; Qiu HX; Li JY; Qian SX
Med Oncol; 2014 Jun; 31(6):980. PubMed ID: 24802329
[TBL] [Abstract][Full Text] [Related]
27. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
[TBL] [Abstract][Full Text] [Related]
28. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP
Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329
[TBL] [Abstract][Full Text] [Related]
29. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
31. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Mele A; Leopardi G; Sparaventi G; Nicolini G; D'Adamo F; Guiducci B; Barulli S; Malerba L; Stramigioli S; Talevi N; Politi P; Isidori A; Malagola M; Piccaluga P; Visani G
Eur J Haematol; 2005 Apr; 74(4):277-81. PubMed ID: 15777338
[TBL] [Abstract][Full Text] [Related]
32. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission.
Kim HJ; Min WS; Eom KS; Park SJ; Park YH; Kim DW; Lee JW; Park CW; Kim CC
Bone Marrow Transplant; 2004 Aug; 34(3):215-20. PubMed ID: 15170169
[TBL] [Abstract][Full Text] [Related]
33. [High-dose chemotherapy of patients with multiple myeloma].
Heyll A; Söhngen D; Aul C; Schneider P; Kobbe G; Bauser U; Quenzel EM; Schneider W
Praxis (Bern 1994); 1998 Jun; 87(25-26):879-83. PubMed ID: 9702091
[TBL] [Abstract][Full Text] [Related]
34. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
[TBL] [Abstract][Full Text] [Related]
35. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Kim H; Park JH; Lee JH; Lee JH; Joo YD; Lee WS; Bae SH; Mo Ryoo H; Lee KH;
Am J Hematol; 2009 Mar; 84(3):161-6. PubMed ID: 19195034
[TBL] [Abstract][Full Text] [Related]
36. High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control.
Capria S; Petrucci MT; Pulsoni A; Ribersani M; Baldacci E; de Propris MS; Meloni G
Acta Haematol; 2006; 115(1-2):9-14. PubMed ID: 16424643
[TBL] [Abstract][Full Text] [Related]
37. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
[TBL] [Abstract][Full Text] [Related]
38. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
39. Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.
Nakasone H; Izutsu K; Wakita S; Yamaguchi H; Muramatsu-Kida M; Usuki K
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1262-9. PubMed ID: 18940681
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Ducastelle S; Adès L; Gardin C; Dombret H; Prébet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E
Haematologica; 2006 Mar; 91(3):373-6. PubMed ID: 16531261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
